Voorhees PM, Laubach J, Anderson KC, Richardson PG (2013) Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood 121(5):858. : 10.1182/blood-2012-11-465765 View Article...
参考文献 Joseph NS,Kaufman JL,Dhodapkar MV. et al.Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.J Clin ...
依据Mayo骨髓瘤分层及风险调整治疗(Mayo Stratification of Myeloma and Risk-adapted Therapy,mSMART)(3.0版本)分期系统进行细胞遗传学危险分层:高危组定义为合并t(4,14)、t(14,16)、t(14,20)、1q21扩增和17p缺失/突变的患者;...
Autologous stem cell transplant as part of initial therapy showed improved progression-free survival in newly diagnosed multiple myeloma patients. News release. ASCO. June 3, 2022. Accessed June 3, 2022. https://bit.ly/3x8IgbqRecent Videos Prior CAR T-Cell Therapy ...
Voorhees PM, Laubach J, Anderson KC, Richardson PG (2013) Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood 121(5):858. : 10.1182/blood-2012-11-465765 View Article...
Life Beyond RVD: The Future of Induction Therapy for Multiple Myeloma - ScienceDirectcellular-based therapyimmunotherapyinduction therapyMMmultiple myelomaproteasome inhibitorsdoi:10.1016/j.clml.2019.07.404Amrita Krishnan MDClinical Lymphoma Myeloma and Leukemia...
Voorhees PM, Laubach J, Anderson KC, Richardson PG (2013) Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood 121(5):858. : 10.1182/blood-2012-11-465765 View Article...
Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as front-line therapy for patients with multiple myeloma (mm): results of a phase 1 study. In: 54th Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA. abstract nr 336....
Our Experience of Using Lenalidomide, Bortezomib and Dexamethasone (RVD) Therapy in Patients with Relapsed/Refractory Multiple Myelomadoi:10.1016/j.clml.2017.07.158PogosyanGayaneClinical Lymphoma, Myeloma and Leukemia
Yago NietoBacteriological ReviewsShah JJ, Feng L, Manasanch EE, et al. Phase I/Ib trial of the efficacy and safety of combination therapy with lenalidomide/bortezomib/dexameth- asone (RVD) and panobinostat in transplant-eligible patients with newly diagnosed multiple myeloma. Blood. 2014;124(21)...